Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EBS Technologies: Stimulating “Silent Neurons” To Restore Impaired Vision

Executive Summary

EBS Technologies GMBH is shattering the current paradigm that once a person loses sight it cannot be regained. Its NEXT WAVE repetitive retinofugal alternate current stimulation technology uses noninvasive electrical stimulation to reactivate networks of “silent neurons” in patients with ophthalmic diseases or who have lost vision following brain injury.

You may also be interested in...



German-Speaking European Associations Collaborate To Focus On Medtech’s Needs

Three central European industry associations have agreed to develop joint initiatives and form a collective voice with which to lobby decision-makers on medtech themes of mutual interest.

EyePoint Hits New Durability Milestone For Wet AMD Treatment

Positive Phase II data in wet AMD showing potential for dosing out to six months could spur partnering interest ahead of Phase III development.

Teva Shows Its Big Pharma Clout With $1.5bn Sanofi Deal

Teva has wrapped up an earlier deal with Sanofi that will see the French giant take command of its novel TL1A inhibitor currently in a Phase IIb study for ulcerative colitis and Crohn’s disease.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel